JLJunli Li

Junli Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junli Li has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Qiang Luo

    Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu 610041, P.R. China

    2 shared publications
  • Chengxiang Song

    Laboratory of Heart Valve Disease, West China Hospital, Sichuan University, #37 Guoxue Alley, Chengdu, 610064, China

    1 shared publication
  • Chengxiang Song

    Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Geer Tian

    Laboratory of Cardiovascular Diseases, Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu 610041, China

    1 shared publication
  • Hao Zhou

    Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Hao-Ran Yang

    Laboratory of Cardiac Structure and Function, Institute of Cardiovascular Diseases, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication

Latest Publications

  • Open Access

    Thrombospondin‐1 Silencing Ameliorates Osteoblastic Differentiation of Aortic Valve Interstitial Cells via Inhibiting Nuclear Factor‐ κ B Pathway

    by Qing Li, Chengxiang Song, Zisong Wei, Junli Li, Hao Zhou, Shuoding Wang, Hongde Li, Haoran Yang, Qiang Luo, Mao Chen

    Objective: Calcific aortic valve disease (CAVD) is a progressive cardiovascular condition driven by the osteogenic differentiation of valve interstitial cells (VICs), with no effective drug therapies currently available. Hence, our objective is to investigate the impact of thrombospondin‐1 (TSP‐1) silencing on CAVD progression. Methods: In vitro experiments were employed using human primary VICs with TSP‐1 knockdown, cultured in osteogenic induction medium, and followed by analyses including western blot, alkaline phosphatase staining, alizarin red staining, immunofluorescence, and flow cytometry. In vivo experiments used two murine models of CAVD to determine the role of TSP‐1 silencing on aortic valve calcification. Results: We observed that silencing of TSP‐1 reduced the osteogenic differentiation of VICs. Subsequent experiments demonstrated that TSP‐1 knockdown suppressed nuclear factor‐ κ B (NF‐ κ B)–mediated inflammation during osteoblastic differentiation of VICs. Consistent findings were also observed in two murine models of CAVD. Conclusions: The present study has shown that TSP‐1 silencing could mitigate the development of CAVD by inhibiting NF‐ κ B‐mediated inflammation. We propose that targeting TSP‐1‐mediated NF‐ κ B pathway could provide a potential therapeutic method for treating CAVD.

  • Open Access

    Intracellular and extracellular synergistic therapy for restoring macrophage functions via anti-CD47 antibody-conjugated bifunctional nanoparticles in atherosclerosis

    by Qiang Luo, Liqun Dai, Junli Li, Heyanni Chen, Ying Hao, Qing Li, Lili Pan, Chengxiang Song, Zhiyong Qian, Mao Chen

    Atherosclerosis is a significant contributor to global cardiovascular disease. Reducing the formation of atherosclerotic plaque effectively can lead to a decrease in cardiovascular diseases. Therefore, controlling macrophage function is crucial. This study presents the creation of a bifunctional nanoparticle that is specific to macrophages to achieve intracellular and extracellular synergistic therapy for restoring macrophage functions. The nanoparticle is conjugated with anti-CD47 antibody to modulate extracellular CD47-SIRPα phagocytic signaling axis on the outer surface of macrophages and encapsulates the NLRP3 inhibitor (CY-09) to regulate intracellular inflammation response of macrophages. The results showed that the nanoparticles accumulate in the atherosclerotic plaque, alter macrophage phagocytosis, inhibit NLRP3 inflammasome activation, and decrease the plaque burden in Apoe-/- mice whilst ensuring safety. Examination of single-cell RNA sequencing indicates that this multifunctional nanoparticle decreases the expression of genes linked to inflammation and manages inflammatory pathways in the plaque lesion. This study proposes a synergistic therapeutic approach that utilizes a bifunctional nanoparticle, conjugated with anti-CD47, to regulate the microenvironment of plaques.


  • Open Access

    Inhibition of P2X7 Purinergic Receptor Ameliorates Cardiac Fibrosis by Suppressing NLRP3/IL-1β Pathway

    by Junteng Zhou, Geer Tian, Yue Quan, Junli Li, Xiaojiao Wang, Wenchao Wu, Miaoling Li, Xiaojing Liu

    P2X7 purinergic receptor (P2X7R) has been implicated in several cardiovascular diseases. However, whether it regulates cardiac fibrosis remains elusive. Herein, its involvement in the development of cardiac fibrosis was examined using a transverse aortic constriction (TAC) mice model and cardiac fibroblasts (CFs) hyperstimulated by TGF-β1 for 48 hours. Results showed that TAC and TGF-β1 treatment increased the expression of P2X7R. Silencing of P2X7R expression with siP2X7R ameliorated TGF-β1 effects on fibroblasts activation. Similarly, P2X7R inhibition by Brilliant Blue G (BBG) reduced mRNA and protein levels of profibrosis markers, while the P2X7R agonist BzATP accelerated the TGF-β1-induced CFs activation. Moreover, it was found that TGF-β1-induced CFs activation was mediated by the NLRP3/IL-1β inflammasome pathway. BBG or siP2X7R treatment suppressed NLRP3/IL-1β pathway signaling. In vivo, BBG significantly alleviated TAC-induced cardiac fibrosis, cardiac dysfunction, and NLRP3/IL-1β activation. Collectively, our findings imply that suppressing P2X7R may limit cardiac fibrosis and abnormal activation of CFs.